The General Hospital Corporation

Other

Cornell Research Foundation Inc.

Sangamo Therapeutics, Inc.

American National Red Cross

University of Iowa Research Foundation

Bradley T Hyman

Rudolph Emile Tanzi

Robert D Moir

Maria Z Kounnas

Dudley K Strickland

Beverly L Davidson

Watt W Webb

H Steve Zhang

Bryan Zeitler

Warren Zipfel

Brian Bacskai

Deborah L Blacker

Annemarie Ledeboer

Sarah DeVos

Susanne Wegmann

Richard Christie

G William Rebeck

George W Rebeck

Shuko Takeda

Eloise Hudry

The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.

Tau modulators and methods and compositions for delivery thereof

The present invention is directed to a method of detecting a neurodegenerative disease in a mammal by activating brain tissue of the mammal by application of radiation under conditions effective to promote a simultaneous multiphoton excitation of the brain tissue and to emit a fluorescence characteristic. The fluorescence characteristic is then compared to a standard fluorescence emitted by exciting healthy brain tissue of the mammal under the same conditions used to carry out the activating step. Brain tissue where the fluorescence characteristic differs from the standard fluorescence is identified as potentially having a neurodegenerative disease. Another aspect of the present invention is directed to a method of producing an image of brain tissue from a mammal by activating brain tissue of a mammal with radiation applied under conditions effective to promote a simultaneous multiphoton excitation of the brain tissue and to produce fluorescence. The fluorescence is then collected to produce an image of the brain tissue.

In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease

The present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid &bgr;-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members of the low density lipoprotein receptor family.

Modulators of expression and function of LRP in Alzheimer's disease

The disclosed invention relates to a diagnostic method for Alzheimer's disease based on genotyping the Alpha-2-Macroglobulin locus. A statistically significant correlation was found between inheritance of particular alleles of the Alpha-2-Macroglobulin gene and the occurrence of Alzheimer's disease. The diagnostic method involves the isolation of nucleic acid from an individual and subsequent genotyping by means such as sequencing or restriction fragment length polymorphism analysis. The invention also provides a means of genotype analysis through protein isotyping Alpha-2-Macroglobulin variant proteins. Finally, kits for nucleic acid analysis or protein analysis are taught.

Alpha-2-macroglobulin diagnostic test

The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid .beta.-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members of the low density lipoprotein receptor family.

Modulators of expression and function of LRP in alzheimer's disease

Growing community of inventors

Swampscott, MA, United States of America

Bradley T Hyman